Kyowa Kirin Terminates its Agreement with Zeria Pharmaceuticals for ASACOL (mesalazine)

 Kyowa Kirin Terminates its Agreement with Zeria Pharmaceuticals for ASACOL (mesalazine)

Kyowa Kirin Signs Two Agreement with Ardelyx to Expand its Existing Partnership

Shots:

  • Kyowa will terminate its sales and marketing activities for ASACOL on Mar 31, 2020. Zeria to get exclusive full rights for sales and marketing for ASACOL from Apr 01, 2020
  • In Jan 2007, Kyowa and Zeria signed an exclusive co-development and co-marketing agreement for ASACOL in Japan
  • ASACOL (mesalazine) is an anti-inflammatory enteric-coated tablet involved in releasing active ingredient mesalazine pH dependently and was launched in Japan in Dec 2009, targeted to treat ulcerative colitis in Japan

Click here to read full press release/ article | Ref: Kyowa Kirin | Image: Pharma World

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post